Drug Design, Development and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model
(7291) Total Article Views
Authors: Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al
Published Date December 2008
Volume 2009:3 Pages 17 - 26
Thilo S Lange1,2, Carolyn McCourt2, Rakesh K Singh2, Kyu Kwang Kim2, Ajay P Singh3, Brian S Luisi4, Onur Alptürk5, Robert M Strongin6, Laurent Brard2
1Division of Biology and Medicine Brown University, Providence, R1, USA; 2Molecular Therapeutics Laboratory, Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants’ Hospital of RI, Warren Alpert Medical School of Brown University, Providence, RI, USA; 3Department of Plant Biology, Rutgers University, New Brunswick, NJ, USA; 4Department of Chemistry, Brown University, Providence, RI, USA; 5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 6Department of Chemistry, Portland State University, Portland, OR, USA
Abstract: The cytotoxicity of organometallic compounds iron(III)-, cobalt(III)-, manganese(II)-, and copper(II)-salophene (-SP) on platinum-resistant ovarian cancer cell lines was compared. Fe-SP displayed selective cytotoxicity (IC50 at ∼1 μM) against SKOV-3 and OVCAR-3 cell lines while Co-SP caused cytotoxic effects only at higher concentrations (IC50 at 60 μM) and Cu-SP effects were negligible. High cytotoxicity of Mn-SP (30–60 μM) appeared to be nonspecific because the Mn-chloride salt reduced cell viability similarly. The effect of Fe-SP at 1 μM proved to be ovarian cancer cell selective when compared to a panel of cell lines derived from different tumors. The first irreversible step in the induction of cell death by Fe-SP occurred after 3 hrs as indicated by the mitochondrial transmembrane potential (ΔΨm) and was mainly linked to apoptotic, not necrotic events. To evaluate the toxicity of Fe-SP in vivo we conducted an acute toxicity study in rats. The LD50 of Fe-SP is >2000 mg/kg orally and >5.5 mg/kg body weight by intraperitoneal injection. An ovarian cancer animal model showed that the chemotherapeutic relevant dose of Fe-SP in rats is 0.5–1 mg/kg body weight. The present report suggests that Fe-SP is a potential therapeutic drug to treat ovarian cancer.
Keywords: iron(III)-salophene, chemotherapeutic properties, p38 MAPK, ovarian cancer animal model
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
- The benefits and risks of testosterone replacement therapy: a review
- Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
- Tenofovir-associated bone density loss